Skin Substitute Codes - JF Part B
Skin Substitute Codes
Effective January 1, 2026, CMS revised payment policies for skin substitute products under Medicare Part B. Most skin substitute products are now paid as incident-to supplies rather than separately payable biologics. CMS has established a single national payment method, updated billing requirements, revised application coding for certain products, and limited use of JW and JZ modifiers to applicable biologic products.
Medicare Part B may cover skin substitute products when they are reasonable and necessary for the treatment of a patient's condition and are billed in accordance with applicable Medicare coverage, coding, and payment requirements.
Skin substitute products include a variety of wound care products derived from synthetic materials, human tissue, animal tissue, and other biologic sources. CMS may classify these products differently for payment purposes than they are classified under FDA regulatory pathways or HCPCS coding descriptors. Providers should follow current CMS billing and payment instructions when reporting skin substitute products and related services.
- CY 2026 Updates
- Pricing
- Non-Sheet Skin Substitute Products
- LCD Withdrawal
- Prior Authorization
- JW and JZ Modifiers
- Documentation Requirements
CY 2026 Updates
Per CMS change request (CR) 14392, Medicare Physician Fee Schedule (MPFS) payment files and billing instructions were updated to reflect the CY 2026 skin substitute payment methodology and associated coding changes.
CMS periodically updates HCPCS codes, payment indicators, and billing instructions through Change Requests, Transmittals, and other program guidance. Providers should refer to the most current CMS publications and Medicare payment files for current coding and payment information.
CMS established generic HCPCS codes Q4431, Q4432, and Q4433 for certain skin substitute products that do not have a product-specific HCPCS code assignment. Providers should report the appropriate code in accordance with current CMS billing instructions.
Providers should monitor Noridian and CMS communications for future updates, as HCPCS coding, payment policies, and product designations may change.
Pricing
Effective January 1, 2026, CMS implemented a national payment method for most skin substitute products classified as non-Biologics License Application (non-BLA) products, including products cleared through the FDA 361 HCT/P, 510(k), and PMA pathways.
Under this method:
- Most skin substitute products are considered incident-to supplies associated with the application procedure.
- Payment is based on the applicable CMS-established rate and billing method rather than the individual product acquisition cost or previously determined ASP.
- Product reimbursement is determined by the documented application service and wound characteristics (surface area) reported on the claim.
- Payment is not made for discarded portions of non-BLA skin substitute products.
- Products cleared under FDA's 351 pathway with a Biologics License Application (BLA) will continue to be considered Biologics with applicable Medicare coverage and reimbursement provisions.
When billing skin substitute application services, providers should report the designated application code and follow current CMS instructions for documentation of wound measurements, units billed, and product used.
Non-Sheet Skin Substitute Products
For certain non-sheet skin substitute products, including products prepared as liquid, gel, paste, powder, or other non-sheet forms, CMS has established HCPCS application codes G0681-G0684.
Providers should report the applicable HCPCS code based on the wound size and total treatment area following current CMS billing instructions.
Do not report duplicate application services for the same treatment encounter.
LCD Withdrawal
Effective January 1, 2026, CMS withdrew the draft Local Coverage Determination (LCD), Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.
Providers should continue to follow applicable Medicare coverage, documentation, coding, and payment requirements, including any future CMS guidance.
Prior Authorization
Skin substitute products are not named on current prior authorization lists associated with the Wasteful and Inappropriate Service Reduction (WISeR).
Providers should continue to watch CMS and contractor communications for any future program changes.
JW and JZ Modifiers
Effective January 1, 2026, JW and JZ modifiers generally do not apply to non-BLA skin substitute products classified as incident-to supplies.
For non-BLA products:
- Do not report the JZ modifier when no product is discarded.
- Do not report the JW modifier for discarded product amounts.
- Bill only the units documented following current CMS billing instructions.
Providers should report JW and JZ modifiers applicable per CMS guidance only for products subject to Biologics coverage and reimbursement.
Documentation Requirements
Providers should ensure documentation supports the procedure performed. Services such as wound debridement, wound care management, and skin substitute applications may have different coding and billing requirements. Refer to LCD L38902 and associated billing and coding guidance, when applicable.
Documentation must support:
- Medical necessity and indications for the service performed.
- Beneficiary's diagnosis and clinical condition, prior treatment and duration of treatment for the specific wound.
- Accurate description of the service rendered, and product used specific to the service rendered (Product name, HCPCS code and quantity in sq.cm.)
- Wound characteristics and measurements, including depth of defect, and calculated surface area treated.
- Services billed to Medicare for the same patient, same day, same condition (wound), same claim.
- Compliance with applicable Medicare coverage, coding, and payment requirements.
Additional documentation guidance is available on the Skin Substitute and Wound Care Documentation Requirements webpage.